2-methylsulfanyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester | 1386980-76-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2-methylsulfanyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester
• 英文别名: methyl 2-methylsulfanyl-7-oxo-8H-pyrido[2,3-d]pyrimidine-6-carboxylate
• CAS: 1386980-76-2
• 化学式: C₁₀H₉N₃O₃S
• 分子量: 251.266
• InChiKey: HJKVXZAIHUEZBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-methylsulfanyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester 在 三氯氧磷 作用下， 生成 Methyl 7-chloro-2-methylsulfanylpyrido[2,3-d]pyrimidine-6-carboxylate
  参考文献：
  名称：

  WO2024067820A1

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氨基-2-甲巯基嘧啶-5-甲醛 、 丙二酸二甲酯 在 potassium carbonate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 以83.3%的产率得到2-methylsulfanyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester
  参考文献：
  名称：

  PYRIDO PYRIMIDINES

  摘要：

  具有该公式的化合物以及它们的药用可接受盐被描述，以及包含所述化合物及其药用可接受盐的药物组合物，以及所述化合物和药物组合物用于治疗、控制或改善增生性疾病，包括癌症、唐氏综合症或早发性阿尔茨海默病的使用。

  公开号：

  US20120184542A1

文献信息

• Chemical compounds as H—PGDS inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11149035B2

  公开（公告）日：2021-10-19

  A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式 (I) 的化合物 其中 R1、R2、R3、R4、X、Y 和 A 如本文所定义。 本发明的化合物是血液前列腺素 D 合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌营养不良症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 H-PGDS 活性和治疗与之相关疾病的方法。
• Chemical Compounds as H-PGDS Inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20200123152A1

  公开（公告）日：2020-04-23

  A compound of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
• [EN] PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS<br/>[FR] PYRIDO PYRIMIDINES UTILISÉES EN TANT QU'INHIBITEURS DE DYRK1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012098065A1

  公开（公告）日：2012-07-26

  Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.